Ann: BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD, page-26

the market isn't looking at the moment ....and the regulatory opportunity with this is not immediate.....so its getting no interest
but when the TGA / FDA see this come through the pile the market interest will follow as pre ind discussions / outcomes are progressed

a table outlining the many studies conducted into the causation of pediatric asd and the research findings and conclusions included below







uncanny similarity in the research findings...exactly what NTI164 is targeting
the global significance of this breakthrough medication is indeed game changing if the appropriate regulatory guidance follows





glah